Oramed extends $20M stock buyback program through June 2026

ORAMED PHARMACEUTICALS INC.

Board extended share repurchase program by one year, now expiring June 2026.
Maximum authorization remains $20M; $2.494M in shares repurchased to date.
Repurchases may occur via open market or private transactions; no obligation to buy.
Board may terminate, increase, or decrease authorization at any time.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.